On CNBC’s “Halftime Report Final Trades,” Jim Lebenthal, partner at Cerity Partners, said Vertex Pharmaceuticals (NASDAQ:VRTX) has nice little chart here over the last few months, up around 30% and expects it to continue.
Lending support to his choice, RBC Capital analyst Brian Abrahams, on Thursday, upgraded Vertex Pharmaceuticals from Sector Perform to Outperform and raised the price target from $455 to $546.
Jenny Van Leeuwen Harrington, CEO of Gilman Hill Asset Management, LLC, said Kimberly Clark (NYSE:KMB) has a 5% yield and is really oversold.
On the earnings front, Kimberly-Clark is scheduled to issue its fourth quarter and full year 2025 results on Tuesday, Jan. 27.
Don’t forget to check out our premarket coverage here
Kari Firestone, co-founder of Aureus Asset Management, said S&P Global Inc (NYSE:SPGI) should really benefit this year from strong debt and capital market cycle pickup.
S&P Global, on Jan. 14, raised its dividend from 96 cents to 97 cents per share.
Joshua Brown, co-founder and CEO of Ritholtz Wealth Management, said he remains long on Exxon Mobil Corp (NYSE:XOM).
Supporting his view, Barclays analyst Betty Jiang maintained Exxon Mobil with an Overweight rating. She also raised the price target from $130 to $140.
Price Action:
- Vertex Pharmaceuticals shares gained 1.4% to close at $467.35 on Thursday.
- Kimberly Clark gained 2.2% to settle at $102.19 during the session.
- S&P Global shares gained 1.6% to close at $539.80 on Thursday.
- Exxon Mobil shares gained 0.1% to close at $133.80 during the session.
Image: Shutterstock
Recent Comments